Brentuximab Vedotin

證據等級: L5

預測適應症: 10 個

Brentuximab Vedotin: From CD30-Positive Classical Hodgkin Lymphoma to Follicular Lymphoma

One-Sentence Summary

Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate internationally approved for CD30-positive classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, but it is not currently marketed in Taiwan. The TxGNN model predicts it may also be effective for Follicular Lymphoma, with 6 clinical trials and 20 publications currently supporting this direction — though most trials are small, terminated/withdrawn, or still recruiting.

Quick Overview

Item	Content
Original Indication	Not specified in this dataset (`original_indications` is empty); BV is internationally approved for CD30-positive classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, per contextual evidence in this pack
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.89%
Evidence Level	L3
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (original_moa is a data gap). Based on the clinical trial and literature evidence collected, brentuximab vedotin is an antibody-drug conjugate combining an anti-CD30 monoclonal antibody with the cytotoxic payload monomethyl auristatin E (MMAE). It binds CD30-expressing cells and delivers the microtubule-disrupting agent intracellularly, and its efficacy in CD30-positive lymphomas has been well established internationally.

Classic follicular lymphoma (FL), however, is not a canonical CD30-high tumor — CD30 expression in FL is typically low or heterogeneous, and is more reliably found in transformed or large-cell-component subsets. The repurposing rationale in this pack explicitly notes that the mechanistic link is only moderate and would require CD30 immunohistochemistry stratification to be clinically meaningful.

This is reflected in the trial landscape: several BV+rituximab/bendamustine combination studies were designed for CD30-positive B-cell lymphomas broadly (including relapsed/refractory FL as one eligible histology), but key trials were terminated or withdrawn before generating conclusive efficacy data. The one FL-specific trial (NCT04587687) is still recruiting with a small planned enrollment (n=23). Overall, the biological rationale is plausible for a CD30-selected FL subpopulation, but direct, mature evidence in unselected FL is currently limited.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02594163	Phase 2	Terminated	25	Randomized, open-label trial of rituximab + bendamustine ± BV for relapsed/refractory CD30-positive DLBCL after second-line failure; terminated without full efficacy readout
NCT04138875	Phase 2	Withdrawn	0	Risk-stratified sequential rituximab + BV (± bendamustine) for newly diagnosed CD20+/CD30+ post-transplant lymphoproliferative disorders; withdrawn before enrollment
NCT04795869	Phase 2	Withdrawn	0	BV + pembrolizumab for recurrent systemic peripheral T-cell lymphoma; withdrawn, no enrollment
NCT02623920	Phase 2	Withdrawn	0	BV + bendamustine + rituximab for CD30-positive relapsed/refractory B-cell NHL; withdrawn, no enrollment
NCT04587687	Phase 2	Recruiting	23	Single-arm study of BV + bendamustine specifically in relapsed/refractory follicular lymphoma; ongoing, no results yet
NCT01805037	Phase 1/2	Terminated	20	BV + rituximab as frontline therapy for CD30+ and/or EBV+ lymphomas; terminated, limited to CD30-positive subset

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35663281	2022	Review	Leukemia research reports	Reviews immunotherapy (including monoclonal antibody-based approaches) across indolent NHL subtypes including follicular lymphoma
32476657	2020	Case report	The Gulf journal of oncology	Grade I follicular lymphoma transforming to CD30+/ALK1- anaplastic large cell lymphoma, achieving complete response to BV plus high-dose methotrexate
40517441	2025	Pending classification	Hematological oncology	Overview of evolving PTCL treatment landscape, including BV-based regimens, across more than 30 disease subtypes
38306597	2024	Pending classification	Blood	Current/upcoming treatment approaches for common nodal PTCL subtypes, including BV combined with CHP for CD30-positive disease
40758949	2025	Pending classification	Blood advances	LYSA phase 2 study of BV + gemcitabine (with BV maintenance) in relapsed/refractory PTCL with ≥5% CD30 expression
39644004	2024	Pending classification	Hematology ASH Education Program	Discusses incorporating BV and novel agents into PTCL management
33320379	2021	Pending classification	European journal of haematology	BV added to ifosfamide/carboplatin/etoposide (ICE) regimen in relapsed/refractory PTCL
28340875	2017	Pending classification	Hematology/oncology clinics of North America	Review of angioimmunoblastic T-cell lymphoma treatment landscape
41409526	2025	Pending classification	Skin appendage disorders	Case of extensive alopecia mucinosa/follicular mucinosis responding to BV
37262395	2023	Pending classification	ASCO Educational Book	Frontline management overview of nodal PTCL subtypes

Note: most of the literature evidence retrieved for this indication concerns CD30-positive T-cell lymphomas (PTCL) rather than follicular lymphoma specifically, reflecting the indirect/mechanistic nature of this signal.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — antibody-drug conjugate (anti-CD30 monoclonal antibody linked to the microtubule-disrupting cytotoxic payload MMAE)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence level is L3 (observational/indirect), and the only trial specifically designed for follicular lymphoma (NCT04587687) is small (n=23) and still recruiting with no results yet; other supporting trials were terminated or withdrawn, and most supportive literature addresses CD30-positive T-cell lymphomas rather than FL directly. Combined with the absence of TFDA safety data and the drug's non-marketed status in Taiwan, the evidence does not yet support proceeding.

To proceed, the following is needed:

TFDA package insert warnings/contraindications (currently a Blocking data gap — required before any S1 safety screening)
Confirmed mechanism-of-action data from DrugBank (currently a High-severity data gap)
CD30 immunohistochemistry stratification data in follicular lymphoma to establish which patient subset the mechanistic rationale actually applies to
Mature results from NCT04587687 (BV + bendamustine in relapsed/refractory FL)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.